Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

This article although dated (2007) show the importance of the T315I mutation in CML patients.

http://www.haematologica.org/content/92/4/437

Unfortunately, I do not believe there is much hope for these patients at present, so if successful BP-1001 might receive accelerated FDA treatment. See this update on CML treatment modalities.


http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-treating-treating-by-phase